Whitelab Genomics
WhiteLab Genomics, founded in 2019 and backed by Y-Combinator, pioneers the accelerated development of genomic medicines using AI and advanced computational methods. Their proprietary ALFRED AI platform combines algorithms, curated databases, and computational biology to optimize therapeutic candidates for safety and efficacy across modalities like AAV, lentivirus, and nanoparticles. The company offers solutions for target receptor identification, vector engineering, payload design, cell therapy, and bioproduction, aiming to de-risk R&D and accelerate the delivery of precise, effective therapies to patients. WhiteLab Genomics operates with a multi-disciplinary team across Paris, Boston, and Montreal.
Whitelab Genomics
WhiteLab Genomics, founded in 2019 and backed by Y-Combinator, pioneers the accelerated development of genomic medicines using AI and advanced computational methods. Their proprietary ALFRED AI platform combines algorithms, curated databases, and computational biology to optimize therapeutic candidates for safety and efficacy across modalities like AAV, lentivirus, and nanoparticles. The company offers solutions for target receptor identification, vector engineering, payload design, cell therapy, and bioproduction, aiming to de-risk R&D and accelerate the delivery of precise, effective therapies to patients. WhiteLab Genomics operates with a multi-disciplinary team across Paris, Boston, and Montreal.
